Linkedin
RLS logo_header
Linkedin

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

“We are excited to deploy Biocytogen’s cutting-edge platforms for antibody discovery to support Adcendo’s innovative ADC drug development initiatives,” said Yuelei Shen, Ph.D., president and CEO of Biocytogen. “Our unique RenMice® platform enables the discovery of fully human antibodies with high affinity, low immunogenicity, and favorable developability. With Adcendo’s extensive expertise in ADCs, we are confident that this collaboration will drive the rapid advancement of novel therapies to benefit patients worldwide.”

Read the full story on "Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development"

Share:

More News

FDA Granted Fast Track Designation for TER-2013 for HR+ve/HER2neg Breast Cancer

“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”

FDA Clears amendment to Open U.S. Enrollment in Ongoing Ph 2 THIO-101 Trial Expansion

“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two

ASCO 2026

Serplulimab Receives Positive CHMP Opinion for the Treatment of sqNSCLC

Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.